Discrepant Diagnostic Results of Nested Polymerase Chain Reaction-based Genotyping in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection

Masami Minemura, Kazuto Tajiri, Yuka Hayashi, Naoki Takahashi, Kasumi Watanabe, Tatsuyuki Hanaoka, Yasuhiro Araki, Kosuke Takahashi, Terumi Takahara, Shigeyuki Kojima and Ichiro Yasuda

Abstract:
Accurate genotyping is important to improve the treatment of hepatitis C virus (HCV) infection. We herein report a 44-year-old Japanese man with hemophilia A and coinfection of HCV and human immunodeficiency virus (HIV) who was diagnosed with HCV genotype 4 by direct sequencing. Two genotyping tests based on the nested polymerase chain reaction method that we used misdiagnosed his genotype as 2b and 1b. Although several HCV genotyping tests are available in Japan, it is important to recognize that some cannot detect genotype 4. Care should be taken when genotyping HCV patients who have received non-heated coagulation factor preparations or were infected abroad.

Key words: hepatitis C virus, direct-acting antiviral agent, genotyping, genotype 4

Introduction
Hepatitis C virus (HCV) infection is a worldwide health problem because it frequently leads to liver cirrhosis and hepatocellular carcinoma. Recent advances in direct-acting antiviral agents (DAAs) have markedly improved the antiviral efficacy in patients with HCV infection (1). Although the latest combination therapy with an HCV protease inhibitor (glecaprevir [GLE]) and an HCV NS5A inhibitor (pibrentasvir [PIB]) is available for several genotypes (2), it is important to determine the genotypes or serotypes of HCV in patients before DAA treatment, as the effects of DAAs differ among genotypes.

Several methods for HCV typing are clinically available, but only serotyping (3), not genotyping, is approved for coverage by the public health insurance program in Japan. The serotyping method can distinguish type 1 (group 1) and type 2 (group 2) with high accuracy (4), but there are a few discrepancies between serotypes and genotypes in some patients that can lead to treatment failure (5-7).

We herein report a patient with HCV and human immunodeficiency virus (HIV) co-infection who initially showed a mismatch between his serotype and the HCV genotype. This is a very rare case, as genotype 2b was first determined using one of the nested polymerase chain reaction (PCR)-based assays, whereas genotype 1b was determined by another genotyping assay. We eventually confirmed the patient’s genotype to be genotype 4 by direct sequencing. We discuss the cause of the discrepancy in genotyping results.

Case Report
A 44-year-old Japanese man was diagnosed with hemophilia A and co-infected with HIV and HCV by the administration of non-heated concentrated coagulation factor preparations in Japan. Although a liver biopsy was not performed because of the patient’s hemophilia, chronic hepatitis C was...
Clinically diagnosed due to liver dysfunction with a persistent elevation of alanine aminotransferase (ALT). He had no splenomegaly and had a liver fibrosis-4 (FIB-4) index of 1.22 (8), so the liver fibrosis was considered non-progressive.

At the patient’s first diagnosis in August 2008, HCV serotyping (3) and HCV RNA quantitative test results led to a diagnosis of serogroup 1, and the HCV RNA titer was 6.40 log IU/mL. In February 2010, we started antiviral treatment with pegylated interferon alfa 2a (Peg-IFNα2a; 180 μg/day) and ribavirin (RBV; 600 mg/day). However, even at 16 weeks after the initiation of this treatment, there was no significant decrease in the patient’s HCV-RNA titer (5.90 log IU/mL), and the treatment was discontinued as a non-response case. The patient’s IL28B genetic polymorphism turned out to be heterozygous (rs8099917 T/G, rs11881222 A/G, rs8103142 T/C) in 2012 (9).

In January 2012 the patient received a combination antiretroviral therapy with abacavir (ABC; 600 mg/day)/lamivudine (3TC; 300 mg/day) and raltegravir (RAL; 800 mg/day) (10). His HIV viral load remained undetectable, and his CD4-positive (CD4+) cell count was over 500/μL.

We considered introducing IFN-free treatment with DAA, and we first used the core region nested PCR method (11) (HCV Genotype Primer Kit; Institute of Immunology, Tokyo, Japan) to determine the patient’s HCV genotype; this method indicated genotype 2b. Although the possibility of a mixed infection of multiple HCV genotypes could not be completely ruled out, we treated the patient with sofosbuvir (SOF; 400 mg/day) and ledipasvir (LDV; 90 mg/day) for 12 weeks beginning in February 2016. He tested negative for HCV RNA at 4 weeks of SOF/LDV treatment, and he achieved a sustained virological response (SVR).

We treated a patient with rare HCV and HIV co-infection for whom it was difficult to determine the HCV genotype by two different nested PCR-based genotyping methods; the genotype was finally determined as genotype 4 by direct sequencing. Since pan-genotype DAAs, such as GLE/PIB, have become available, the importance of genotyping has diminished. However, accurate genotyping is still useful for determining the appropriate duration of treatment for chronic hepatitis in Japan, as the duration differs between genotype 1/2 and other types according to the current guidelines for the treatment of HCV issued by the Japanese Society of Hepatology (15). Accurate genotyping of HCV can achieve a high SVR.
In Japan, an HCV serotyping assay using non-structural protein 4 (NS 4)-specific antibodies is commonly used (3), as an HCV genotyping assay based on the nested PCR method is not approved for coverage by the national health insurance program. When determining HCV genotypes, the frequency of discrepancy between the serotype and genotype is reported to be low (4, 16, 17), but some clinically problematic cases have been reported (5-7). Such discrepancies may be caused by coinfection of different genotypes of HCV (6) or infection with an intergenotypic recombinant virus (7).

The genotype reportedly cannot be accurately determined even when performing genotyping using nested PCR methods targeting the core region, such as genotyping with an HCV genotype primer kit (5). In the present case, we used two types of genotyping test kits based on nested PCR targeting the core region: an HCV genotype primer kit based on Okamoto’s method (11), and an HCV RNA core genotype kit based on Ohno’s method (12). The first kit can detect genotypes 1a, 1b, 2a, 2b, and 3a, but not 4, as the kit does not include the setting of PCR primers for genotype 4. With this kit, our patient was misidentified as genotype 2b. The HCV genotyping system that was originally reported by Ohno et al. can detect genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a (12), but the commercially usable diagnostic kit (HCV RNA Core Genotype Kit) has no setting of PCR primers for genotypes 4, 5a, and 6a. This assay also provided an incorrect result (genotype 1b) for our patient.

Direct sequencing performed to determine the patient’s exact genotype revealed genotype 4, which was not initially expected (Fig. 2, 3). The mistaken results with the first two methods may have been due to the corresponding site of this HCV strain having a relatively high homology for each specific primer (Table) and there being no suitable primer for genotype 4. Because ultra-deep and whole genome sequencing was not performed, the possibility of a mixed HCV genotype infection or an intergenotypic recombinant viral infection could not be completely ruled out. This is a limitation of this case report.

HCV genotype 4 accounts for up to 13% of all HCV infections worldwide and is found frequently in North and Central Africa and the Middle East (18). Hayashi et al. reported that the prevalence of genotype 4 was very low in Japan (0.4%) and that all of the individuals with genotype 4 were male hemophiliacs who received concentrated coagulation factor preparations from abroad (19). Our patient was also diagnosed with hemophilia A and had previously been given non-heat concentrated coagulation factor preparations.

The guidelines from the European Association for the Study of the Liver (EASL) recommend several DAA combination therapy regimens as anti-HCV therapy for patients with HCV genotype 4 infection (1). Since SOF/LDV has

---

**Figure 2.** A molecular phylogenetic tree that analyzes whether or not a test virus strain belongs to a known hepatitis C virus genotype strain. The genetic distance was estimated using the Kimura two-parameter method, and the tree was constructed using a neighbor-joining method.
genotyping assays failed to determine the exact genotype. HCV genotype 4 infection in whom two usable nested PCR lapsed after treatment with SOF/RBV. In conclusion, we reported a rare case of a patient with an 4 (13), we have administered SOF/LDV to patients who re-lapsed after treatment with SOF/RBV. The authors state that they have no Conflict of Interest (COI).

Japan, but it is important to recognize that some testing kits cannot detect genotype 4. Care should be taken when genotyping HCV-infected patients who have been given non-heated coagulation factor preparations or were infected abroad.

The authors state that they have no Conflict of Interest (COI).
Acknowledgement
We thank Megumi Minemura for her technical support.

References
1. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 69: 461-511, 2018.
2. Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 16: 417-426, 2018.
3. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19: 1347-1353, 1994.
4. Mizoguchi N, Mizokami M, Orito E, Shibata H, Shibata H. Serologically defined genotypes of hepatitis C virus among Japanese patients with chronic hepatitis C. J Virol Methods 58: 71-79, 1996.
5. Ishikawa T, Abe S, Kojima Y, Kojima S, Yoshida T. Discrepant diagnostic results using two genotyping methods in a chronic hepatitis C patient in serogroup 1. Hepatol Res 46: 354-356, 2016.
6. Sohda T, Yamauchi E, Anan A, et al. Non-response to daclatasvir and asunaprevir therapy in patients co-infected with hepatitis C virus genotypes 1 and 2. Hepatol Res 47: 364-367, 2017.
7. Kurata H, Uchida Y, Koyama J, et al. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res 48: E372-E378, 2018.
8. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46: 32-36, 2007.
9. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109, 2009.
10. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 374: 796-806, 2009.
11. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 74: 2385-2390, 1993.
12. Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 35: 201-207, 1997.
13. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: A proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 15: 1049-1054, 2015.
14. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373: 705-713, 2015.
15. Hepatitis C treatment guidelines (8th edition), edited by the Japanese Society of Hepatology [Internet]. 2020 [cited 2021 Feb 2021]. Available from: http://www.jsh.or.jp/medical/guidelines/jsh_guidelines/hepatitis_c.
16. Hoshino H, Hino K, Miyakawa H, Takahashi K, Akbar SM, Mishiro S. Inter-genotypic recombinant hepatitis C virus strains in Japan noted by discrepancies between immunoassay and sequencing. J Med Virol 84: 1018-1024, 2012.
17. Inoue J, Kanno A, Wakui Y, et al. Identification of genotype 2 HCV in serotype-1 hepatitis C patients unresponsive to daclatasvir plus asunaprevir treatment. Tohoku J Exp Med 241: 21-28, 2017.
18. Hathorn E, Elsharkawy AM. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol 3: e000112, 2016.
19. Hayashi K, Fukuda Y, Nakano I, et al. Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers. Hepatol Res 25: 409-414, 2003.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).